Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

While tocilizumab (TCZ) is known to increase low‐density lipoprotein (LDL) cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with rheumatoid arthritis (RA). This study was undertaken to compare the cardiovascular risk associated with receiving TCZ versus tumor necrosis factor inhibitors (TNFi).

[1]  J. Listing,et al.  Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis , 2016, Arthritis Research & Therapy.

[2]  N. Wong,et al.  A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. , 2016, The American journal of cardiology.

[3]  J. Singh,et al.  Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[4]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[5]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[6]  I. McInnes,et al.  Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[7]  J. Singh,et al.  Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration , 2015, Annals of the rheumatic diseases.

[8]  D. Solomon,et al.  Active-comparator design and new-user design in observational studies , 2015, Nature Reviews Rheumatology.

[9]  K. Liao,et al.  Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non–Rheumatoid Arthritis Patients , 2015, Arthritis & rheumatology.

[10]  N. Sattar,et al.  An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy , 2015, Arthritis & rheumatology.

[11]  W. Gulliver,et al.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.

[12]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[13]  R. Hansen,et al.  Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study , 2014, The Journal of Rheumatology.

[14]  B. Kissela,et al.  Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims , 2014, Circulation. Cardiovascular quality and outcomes.

[15]  Jeremy A Rassen,et al.  Metrics for covariate balance in cohort studies of causal effects , 2014, Statistics in medicine.

[16]  I. McInnes,et al.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm , 2013, Nature Reviews Rheumatology.

[17]  Mary K. Kowal,et al.  Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. , 2013, The American journal of medicine.

[18]  R. Leonhart,et al.  Researcher allegiance in psychotherapy outcome research: an overview of reviews. , 2013, Clinical psychology review.

[19]  P. Emery,et al.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial , 2013, The Lancet.

[20]  J. Avorn,et al.  Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments , 2012, BMC Medical Research Methodology.

[21]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[22]  F. Cunningham,et al.  US Government Claims Databases , 2012 .

[23]  J. Gurwitz,et al.  A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.

[24]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[25]  W. Ghali,et al.  Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis , 2011, Arthritis care & research.

[26]  Jeffrey N Katz,et al.  Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.

[27]  T. Therneau,et al.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease , 2011, Annals of the rheumatic diseases.

[28]  M. Hochberg,et al.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[29]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[30]  M. Hochberg,et al.  Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity , 2010, Annals of the rheumatic diseases.

[31]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[32]  Mohsen Sadatsafavi,et al.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.

[33]  Jeffrey N Katz,et al.  Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study , 2008, Arthritis research & therapy.

[34]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[35]  Ken Kleinman,et al.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  A. Silman,et al.  Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register , 2007, Arthritis and rheumatism.

[37]  M. Cutolo,et al.  Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .

[38]  A. Silman,et al.  The British Society for Rheumatology Biologics Register , 2005, Annals of the rheumatic diseases.

[39]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[40]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[41]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[42]  A. Silman,et al.  British Society for Rheumatology Biologics Register , 2003, Annals of the rheumatic diseases.

[43]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[44]  Peter Cummings,et al.  Matched-pair cohort methods in traffic crash research. , 2003, Accident; analysis and prevention.

[45]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[46]  K. Rothman,et al.  VASECTOMY AND NON-FATAL MYOCARDIAL INFARCTION , 1981, The Lancet.